6.2 FDA Approval, Recalls, and OTC vs Rx
Key Takeaways
- Hatch-Waxman (1984) created the ANDA under FDCA § 505(j) for small-molecule generics; a full NDA remains § 505(b); biologics are licensed under PHS Act § 351, not as ANDAs.
- The Orange Book lists NDA/ANDA products and therapeutic-equivalence codes (A/AB versus B); the Purple Book lists licensed biologics, biosimilars, and interchangeable biologics.
- Class I recall: reasonable probability of serious adverse health consequences or death, generally consumer-level; Class II: temporary or reversible harm or remote serious harm, generally retail; Class III: not likely to cause harm, generally wholesale.
- A market withdrawal is not a recall. Most drug recalls are manufacturer-initiated; FDA classifies and oversees them under 21 CFR Part 7 and may request or order a recall where statute allows.
- When a recall hits, quarantine matching lots, stop dispensing them, and follow the firm's and FDA's instructions—Class I consumer-level notices generally include patient contact. CT may be stricter; more-restrictive wins.
Why approval status and recall class are tested
Quick Answer: An ANDA under Hatch-Waxman (FDCA § 505(j)) is how FDA approves a small-molecule generic; biologics are licensed under PHS Act § 351. Look up tablets in the Orange Book (A/AB versus B therapeutic-equivalence codes) and biologics in the Purple Book (biosimilar versus interchangeable). Class I recalls carry a reasonable probability of serious harm or death; Class II temporary or remote serious harm; Class III not likely to cause harm. Most recalls are manufacturer-initiated; FDA classifies and oversees. Quarantine the lots and follow the notice.
NABP 2.5 and the DSCSA/FDCA overlay both assume you can tell an approved generic from a biologic, and a Class I recall from a market withdrawal. Connecticut substitution (CGS § 20-619, Chapter 14) will teach how a pharmacist substitutes; this section teaches the federal listing those statutes point to. FDA.gov and 21 CFR Part 7 are the primary sources. Connecticut Drug Control can still cite you for leaving recalled stock in active inventory. CT may be stricter; more-restrictive wins.
NDA, ANDA, and Hatch-Waxman
A New Drug Application (NDA) under FDCA § 505(b) (21 U.S.C. § 355(b)) is the full federal package that demonstrates safety and effectiveness for a specified use. A 505(b)(1) NDA contains the sponsor's own investigations. A 505(b)(2) NDA may rely in part on studies not conducted by the applicant (published literature or FDA's findings on a listed drug). Neither pathway is 'generic approval.'
The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman) created the Abbreviated New Drug Application (ANDA) under § 505(j). An ANDA does not repeat the innovator's clinical program. The applicant must show that the generic is the same as the reference listed drug (RLD) in active ingredient, dosage form, strength, route, and labeling (with permitted differences), and that it is bioequivalent. Approval of an ANDA is what puts a substitutable small-molecule generic on the market.
Biologics are licensed under § 351 of the Public Health Service Act (42 U.S.C. § 262), not under an NDA. A biosimilar is highly similar to the reference product with no clinically meaningful differences in safety, purity, or potency. An interchangeable biologic is a biosimilar that meets the extra PHS Act standard: it can be expected to produce the same clinical result in any given patient, and for a product administered more than once, the risk of alternating or switching is not greater than using the reference without switching. Insulin and certain other proteins that once sat in the Orange Book transitioned to biologics licenses on March 23, 2020 and now live in the Purple Book.
Federal listing: Orange Book versus Purple Book
| Book | What it lists | Pathway | Substitution signal |
|---|---|---|---|
| Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) | Small-molecule drugs approved under FDCA § 505 (NDAs and ANDAs) | ANDA 505(j); TE codes | A-rated (commonly AB) products are therapeutically equivalent to the RLD; B-rated are not |
| Purple Book (database of licensed biological products) | Biologics licensed under PHS Act § 351, including biosimilars and interchangeables | 351(k) biosimilar / interchangeable | Biosimilarity is not automatic pharmacy substitution; interchangeability is the federal substitution designation |
Do not look up a monoclonal antibody in the Orange Book, and do not look up a hydrochlorothiazide tablet in the Purple Book. Connecticut will decide how a pharmacist substitutes under CGS § 20-619; the federal books tell you whether FDA has even made a therapeutic-equivalence or interchangeability finding. Chapter 14 goes deeper on state substitution mechanics.
Rx versus OTC at the counter
FDCA § 503(b) still divides human drugs into two classes. Prescription (Rx-only) drugs are those that are not safe for use except under practitioner supervision, or that are limited to prescription use by approved labeling. OTC drugs can be labeled with adequate directions for a layperson to use safely. Moving a drug from Rx to OTC is a federal FDA decision (typically a supplemental NDA or an OTC monograph change), not a Connecticut Commission vote.
Consequences at a Connecticut bench:
- Dispensing an Rx-only product without a valid prescription misbrands it under § 502
- Stocking an OTC product is still subject to adulteration and misbranding, to CMEA limits if it contains pseudoephedrine (section 6.3; full BTC rules in Chapter 14), and to Connecticut nonlegend-drug permit rules (Chapter 419 / CGS § 20-624)
- A pharmacist cannot 'switch' an Rx drug to OTC because the patient asked, and cannot refuse to sell a lawfully marketed OTC solely because 'Connecticut has not approved it'
The tighter of FDA class and Connecticut retail-drug rules controls the sale.
Recalls: Class I, II, and III
FDA classifies recalls by risk. 21 CFR Part 7 and FDA's current recall pages (definitions current as of March 2026; consumer explainer current as of May 2026) use these definitions:
| Class | FDA definition | Typical depth | Patient use until told otherwise |
|---|---|---|---|
| Class I | Reasonable probability that use or exposure will cause serious adverse health consequences or death | Generally consumer level; urgent removal | Follow the recalling firm's and FDA's instructions; usually stop use of the affected lots |
| Class II | Use or exposure may cause temporary or medically reversible adverse health consequences, or the probability of serious consequences is remote | Generally retail level | Patients may continue unless the recalling company or FDA directs otherwise |
| Class III | Use or exposure is not likely to cause adverse health consequences (minor labeling, packaging, or dating defects) | Generally wholesale level | Continue unless directed otherwise |
A market withdrawal is not a recall. It is a firm's removal or correction of a minor violation that would not be subject to FDA legal action (for example, isolated tampering without evidence of a manufacturing or distribution problem). Do not treat a market withdrawal as a Class III recall on the exam.
Who starts the recall. Most drug recalls are manufacturer-initiated (voluntary). FDA may request a recall, classifies it, and oversees the strategy and effectiveness under 21 CFR Part 7. FDA may order a recall where statute allows, and can seize product, seek an injunction, or publicize if a voluntary recall is ineffective. The pharmacist's duty does not wait for a DCP letter. A manufacturer letter and an FDA Enforcement Report are enough to act.
Pharmacist duty when a recall hits
When a notice names NDCs, lots, or serials that you stock or have dispensed:
- Match the NDC, lot, or serial against on-hand inventory, including robots, will-call, night cabinets, and compounding stock
- Quarantine affected packages immediately; do not leave them in active canisters with a sticky note
- Stop dispensing the affected lots
- Identify patients who received those lots when the recall is consumer-level (especially Class I) and follow the recalling firm's and FDA's contact instructions
- Document what you found, whom you notified, and how you disposed of or returned the stock
- Notify the pharmacist manager / PIC and follow the pharmacy's written recall procedure
- Check FDA Enforcement Reports if the manufacturer letter is incomplete
A Class II or III recall generally does not require calling every patient unless the notice says so. A Class I consumer-level recall does. Telling a patient to 'keep taking it until DCP inspects us' is the wrong instinct. Stopping a chronic medicine without a plan can also harm the patient—follow the notice, then coordinate a replacement lot or an alternative with the prescriber.
Scenario: two notices, one week
A Stamford pharmacy receives a manufacturer Class I notice for a lot of injectable product with a reasonable probability of bacterial contamination. The same week, a wholesaler announces a Class III recall for a bottle whose outer carton has a transposed NDC but the inner label is correct. The pharmacist must pull and quarantine the injectable lots, identify patients who received them, and follow the Class I instructions. The carton-only Class III product is pulled from the shelf per the notice, but there is no automatic duty to phone every patient. Treating both events as 'just Class III because nobody died yet' fails the FDA classification. Leaving either lot in the robot is a quality failure DCP can cite even if FDA never visits.
Connecticut may add quarantine, documentation, or patient-notice expectations on top of FDA's floor. CT may be stricter; more-restrictive wins.
Official anchors
- FDA Orange Book preface — NDA/ANDA listing and Hatch-Waxman.
- FDA Purple Book background — biosimilarity and interchangeability.
- FDA recall definitions and Understanding Drug Recalls — Class I/II/III and FDA's oversight role.
FDA classifies a recall of an injectable whose use carries a reasonable probability of serious infection or death. What class is that, and at what depth is it generally conducted?
A Connecticut pharmacist needs to know whether FDA has rated a tablet therapeutically equivalent to its reference listed drug, and whether a separately named biologic is interchangeable with its reference product. Which federal listings apply?
A manufacturer issues a Class I consumer-level recall for lots a New Haven pharmacy has already dispensed. The pharmacist waits for a DCP inspector because 'only FDA-ordered recalls count, and Class I never requires patient contact.' Which statement is correct?